The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Monthey, Switzerland
1-10 Employees
2023
Most protein-based therapeutics in regenerative medicine have limited success due to uncontrolled drug delivery, which can result in side effects and high costs. Our technology modifies therapeutic proteins to improve delivery through controlled localization, for enhanced efficacy and reduced dosage. The limited clinical success of many protein-based therapeutics is often due to subpar delivery systems. The injected molecule tends to quickly diffuse away from the injection site, which is a problem especially in regenerative medicine where local action is crucial for tissue regeneration and repair.Our technology solves this issue by allowing precise control over the delivery of the medication. By modifying therapeutic proteins to incorporate a built-in delivery system, we ensure they remain at the targeted injection site. The absence of optimal delivery system usually calls for large doses of therapeutic protein to be administered. As a first application we developed a molecule protecting the cardiac muscle following a heart attack, reducing fibrosis and cellular death, and preserving the cardiac function.
+
Featured
Redefining regeneration through protein engineering
... Redefining regeneration through protein engineering ...
Pasadena, United States
1-10 Employees
2009
Protabit is preparing to release TriadWeb, a web-based, protein design service built upon Protabit’s Triad software platform and utilizing the Amazon Elastic Compute Cloud. Protabit is developing Triad into a web-based, easy-to-use, collaborative CPD software application that is available by subscription, without the hassle of installing software or purchasing and maintaining expensive hardware. Barry Olafson, Protabit CEO and co-founder, is the principal investigator on the NIH project. Protabit is providing the computational protein design software and engineering expertise. Protabit will apply its computational protein design software to engineer improved MMOs. Stephen Mayo, Protabit co-founder and Chair of the Division of Biology and Biological Engineering at Caltech. Barry Olafson, Protabit CEO and co-founder added, “We are pleased to receive this grant from the NSF, which will allow us to develop a platform for optimizing an MMO for industrial use. At the core of Protabit’s engineering approach is Triad, a computational protein design software platform that is used to generate new enzymes for experimental evaluation.
+
Featured
A Modern, Open Protein Engineering Database.
... National Institutes of Health awards Fast-Track Small Business Innovative Research grant to develop a database for protein engineering ...
Shenzhen, China
11-50 Employees
2020
Synthetic organelles in PandaPure provide a distinct environment for protein folding and maturation, and also protect hosts from potential toxicity of expressed proteins, leading not only a broadened scope of applicable proteins in E.
+
Featured
Ailurus Bio - Program biology like computers
... Synthetic biology, Generative AI, Ultra-high-throughput experiments, Protein engineering, Cell programing...Ailurus provides end-to-end services for biology research and development. Featured Service: Ailurus Protein Service, enabling protein engineering with exceptional ...
Seattle, United States
1-10 Employees
2017
Olympic Protein Technologies (OPT) is a contract research organization focused on providing high-quality protein science services for clients and partners. OPT currently offers construct design, expression, protein production & characterization, biomolecular interaction analysis, and protein engineering services. Our goal is to facilitate the success of your project through excellent work and clear communication. The aim of our team is to leverage this knowledge to provide the best experience and outcomes for our partners and clients by providing quality science delivered with full engagement and the highest standards, integrity, and data security. We also can leverage our network of protein science contacts to provide access to other types of analyses, such as advanced biophysical technologies, for your project. As we grow we will build on our existing capabilities while broadening our offerings to include additional protein science services. Prior to founding Olympic Protein Technologies, Mike served as the Chief Scientific Officer at ContraFect Corporation leading the team to build their discovery and development pipeline including CF-301, CF-296, and CF-404 for the treatment of infectious diseases. High protein expression through DNA sequence optimization and cloning into specialized expression vectors.
+
Featured
Olympic Protein Technologies | Custom Protein Production
... Protein Engineering ...
Tainan, Taiwan
51-100 Employees
2013
Our mission is to diminish the dependency on imported biological materials, enhance the landscape of Taiwan's biotech industry, and boost its global standing. Additionally, we provide a range of scientific research products and professional technical systems in immunology and biochemistry. Beyond profit generation, we are dedicated to the well-being of our employees, society, and the environment. Our goal is to foster a positive social impact while enhancing overall economic benefits. We provide premium quality reagents through creative and scientific approaches, with production standards outlined in quality management systems ISO 13485, and GMP/QMS guidance. Leadgene Biomedical is dedicated to technological innovation and the creation of visionary products. Our ambition is to emerge as a leading, groundbreaking, and globally recognized biotech company in Taiwan. We collaborate with world-renowned experts and partners to build a diverse and competitive team, ensuring alignment with international standards.
+
Featured
Protein Engineering
... Protein Engineering ...
Lausanne, Switzerland
11-50 Employees
This data provides feedback and augments the AI models at each round in order to optimize the functional profile of the next set of protein designs. Our foundry is being built from the ground up to integrate with AI at every step of the protein engineering cycle - from designing sequences, to planning experimental protocols, to running those experiments autonomously and tracking all data and metadata.
+
Featured
Next-generation Protein Engineering
... Making Engineering Proteins As Easy As Using An ...
Inglewood, United States
11-50 Employees
2013
AMDI will launch its first products from its ISO:13485 certified 110,000 square foot facility in Santa Ana, CA. Create patient-centric and cloud-connected diagnostics that provide actionable information within minutes. Christopher Bissell has more than 20 years of experience in corporate finance and accounting including responsibility for all aspects of the accounting function. AMDI offers opportunities for collaboration that would leverage our protein engineering, microfluidics and manufacturing expertise.
+
Featured
Protein Engineering – AMDI Labs
... Protein Engineering – AMDI ...
Middleton, United States
1-10 Employees
StableBody Technologies, LLC is offering its rational protein design technology as a User Interface Application for scientists everywhere working with amino acid sequence alignment data in protein design and engineering from their lab bench base with built-in automation components for design work.
+
Featured
Technology — StableBody Technologies, LLC
... These novel, proprietary bioinformatic algorithms are making huge improvements in the protein engineering field. ...
Germany
1-10 Employees
2008
Working with SeSaM-Biotech could not have been more satisfying. Since its establishment in 2008, SeSaM-Biotech is dedicated to first-class Directed Enzyme Evolution, also known as Protein Engineering, with a special focus on mutagenesis, assay development and application as well as computational design of enzymes to provide our customers the Quality Enzyme Solutions. With the excellent RWTH Aachen University nearby, SeSaM-Biotech is at the very right spot to conduct its innovative research for institutions and industry worldwide that use enzymes in their products and processes. Discuss your enzyme and desired property improvements with our specialists and receive an offer outlining our strategy to evolve your enzyme. Follow the progress of your Directed Evolution project via regular project updates provided to your mailbox and via telephone calls. Receive your improved enzyme ready for implementation in your process or product.
+
Featured
Protein engineering and directed evolution
... We love to contribute to your success with our expertise in Directed Enzyme Evolution covering the areas of Protein Engineering, Assay Development, Gene Library Design and more. Get in touch to learn more about our Patented Protein Engineering – Made in Germany. ...
San Francisco, United States
1-10 Employees
2014
Revitope Oncology is revolutionizing immunotherapy to safely and effectively treat more cancers, bringing hope to patients for healthier and longer lives. Revitope is transforming the way immunotherapeutic drugs are designed. Revitope is led by a team of creative, highly engaged scientists and industry veterans who have deep experience in protein engineering and immunotherapy with a proven track record of delivering effective biologic therapies that treat cancer and other serious immunological diseases. Revitope’s platform is a suite of proprietary and modular bispecific antibodies designed to deliver improved therapeutic efficacy and safety through built-in control mechanisms that enable exquisite tumor-specificity. Revitope, the Revitope logo and TwoGATE™ are registered trademarks of Revitope Oncology Inc. Revitope’s PrecisionGATETM Technology Platform is designed to develop antibody-based bispecific immunotherapies that minimize toxicity to widen the therapeutic window and provide more efficacious cancer treatments. Revitope’s proprietary Precision Guided Antibody Tumor EngagerÔ (PrecisionGATE) technology platform exploits co-expressed tumor antigens to enable the development of highly specific cancer drugs with improved safety and efficacy over conventional immunotherapeutic approaches. Revitope will leverage its proprietary protein engineering platform together with Junshi’s novel antibody components to develop first-in-class dual-antigen targeting cancer therapies.
+
Featured
Revitope Oncology Inc. - Powered for Precision
... Revitope Oncology is a biotech company leveraging biological insights and protein engineering to develop a new class of cancer immunotherapies powered for precision. ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Protein Engineering
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 71 |
| Amount of suitable service providers | 47 |
| Average amount of employees | 1-10 |
| Oldest suiting company | 2008 |
| Youngest suiting company | 2023 |
Protein engineering is the process of developing useful or valuable proteins through the modification of amino acid sequences, employing techniques like rational design and directed evolution. This innovative field intersects with biochemistry, molecular biology, and genetic engineering, aiming to produce proteins with enhanced properties or functions that are not found in nature. By altering the structure of proteins, scientists can improve their stability, increase their efficiency as enzymes, optimize their binding affinity to other molecules, or even create entirely new functionalities. This methodological alteration and design have widespread applications across various industries, including pharmaceuticals, where engineered proteins play a pivotal role in developing new therapeutics and diagnostics. In agriculture, protein engineering contributes to the creation of crops with improved nutritional profiles or resistance to pests and diseases. Furthermore, in the environmental sector, engineered proteins are used in bio-remediation processes to degrade pollutants more efficiently. The impact of protein engineering extends to the energy field as well, where it aids in the development of biofuels by enhancing the efficiency of enzymes involved in biomass conversion. The strategic manipulation of protein structures through protein engineering not only deepens our understanding of protein function and structure but also paves the way for innovations that address some of the most pressing challenges in healthcare, agriculture, and environmental sustainability.
1. Enhanced Efficiency
Protein engineering allows for the specific alteration of amino acid sequences, leading to enzymes and proteins that perform their functions more efficiently than their natural counterparts. This precision enhances the catalytic properties of enzymes used in industrial processes, making them more effective and cost-efficient.
2. Improved Stability
Through protein engineering, proteins can be designed to have increased thermal and chemical stability. This is particularly beneficial in pharmaceutical and industrial applications where proteins may be exposed to harsh conditions. The enhanced stability reduces the degradation rate, extending the shelf life and usability of protein-based products.
3. Customization for Specific Applications
One of the most significant advantages of protein engineering is the ability to tailor proteins for specific applications. By modifying the structure of proteins, scientists can create molecules with properties that are not found in nature, such as binding to unique targets or catalyzing novel reactions. This level of customization opens up new possibilities in medicine, agriculture, and environmental management.
4. Reduced Immunogenicity
Protein engineering can be used to reduce the immunogenicity of therapeutic proteins, making them safer for clinical use. By modifying protein sequences, engineers can minimize the risk of adverse immune responses, improving the efficacy and safety profile of biopharmaceuticals.
1. Experience and Expertise
Evaluate the supplier's track record in protein engineering, including the complexity of projects handled and the innovation demonstrated in past projects.
2. Technological Capabilities
Ensure the supplier has access to advanced technologies and equipment for protein design, synthesis, and screening.
3. Quality Control Measures
Check for stringent quality control processes in place to ensure the integrity and functionality of engineered proteins.
4. Customization and Flexibility
The supplier should offer customization options and be flexible in adapting to specific project requirements and changes.
5. Scalability
Consider the supplier's capacity to scale operations, from small-scale prototypes to large-scale production, without compromising on quality.
6. Regulatory Compliance
Verify the supplier’s adherence to relevant regulations and standards in protein engineering to ensure compliance and reduce project risks.
7. Cost-effectiveness
Assess the cost structure of the supplier’s services to ensure it aligns with budget constraints while still delivering high-quality results.
Protein engineering has revolutionized the pharmaceutical industry by enabling the design of protein-based drugs with improved efficacy and reduced side effects. Through the precise modification of protein structures, companies can develop therapeutics that are more specific to disease targets, enhancing treatment outcomes and patient safety. This advancement facilitates the creation of a new generation of biologics, including antibodies and vaccines, tailored for various conditions ranging from cancer to autoimmune diseases. In the agricultural sector, protein engineering plays a pivotal role in developing crops with enhanced nutritional profiles, resistance to pests and diseases, and improved tolerance to environmental stresses. By altering the proteins involved in plant growth and defense mechanisms, researchers can produce varieties that yield more nutritious and robust crops. This innovation supports sustainable farming practices and addresses food security challenges by improving crop resilience and productivity. The environmental industry benefits from protein engineering through the development of bio-catalysts for pollution control and waste management. Engineered enzymes are increasingly used in bioremediation processes to break down pollutants and toxic compounds in water and soil, offering a green and efficient alternative to conventional chemical treatments. This technology paves the way for cleaner production processes and sustainable environmental management practices, highlighting the versatile applicability of protein engineering across diverse industries.
Protein engineering, a pivotal field within biotechnology, is currently estimated to be at various Technology Readiness Levels (TRLs) ranging from 4 to 7, depending on the specific application and technique employed. This broad TRL range reflects the transition from small-scale laboratory validation (TRL 4) to the integration and demonstration of the technology in relevant environments (TRLs 5-6), and eventually to system prototype demonstration in operational environments (TRL 7). The reason for this span in readiness levels lies in the technical complexities and challenges associated with manipulating protein structures for desired functions. Innovations in computational biology and bioinformatics have propelled the field forward, allowing for more accurate modeling and simulation of protein behaviors. However, the intricate nature of protein folding and the effects of even minor modifications on protein function present significant hurdles to achieving consistent, predictable outcomes at a large scale. Furthermore, while some protein engineering techniques have successfully been applied to create novel enzymes for industrial processes, translating these successes to other applications, such as therapeutic protein development, is often more complex due to stringent regulatory requirements and the need for extensive validation in clinical settings. Consequently, the variability in TRLs underscores the dynamic and evolving nature of protein engineering, highlighting both its potential and the challenges that remain to be addressed.
In the Short-Term, advancements in protein engineering are set to revolutionize biotechnology and pharmaceutical industries. With the integration of machine learning algorithms, the next few years will witness a significant reduction in the time and cost associated with the development of new proteins. This will facilitate the rapid design of enzymes for biofuels, improving sustainability and environmental impact. The Mid-Term phase will see the emergence of precision medicine, propelled by protein engineering. Customized therapeutic proteins, tailored to individual genetic profiles, will become more commonplace, offering targeted treatments for a broad spectrum of diseases. This period will also mark the advent of more sophisticated methods for protein structure prediction, enhancing our understanding of disease mechanisms and accelerating drug discovery processes. Looking into the Long-Term, the horizon of protein engineering is expected to expand into the creation of completely novel proteins that could give rise to new biological functions and materials. These innovations could pave the way for breakthroughs in nanotechnology and materials science, leading to the development of biomaterials with unprecedented properties. This era might also witness the advent of synthetic biology applications, where engineered proteins play crucial roles in creating living systems with new capabilities.
